Monopar Therapeutics Statistics Share Statistics Monopar Therapeutics has 6.12M
shares outstanding. The number of shares has increased by 73.71%
in one year.
Shares Outstanding 6.12M Shares Change (YoY) 73.71% Shares Change (QoQ) 0.21% Owned by Institutions (%) 4.13% Shares Floating 3.95M Failed to Deliver (FTD) Shares 1,611 FTD / Avg. Volume 4.3%
Short Selling Information The latest short interest is 136.52K, so 2.23% of the outstanding
shares have been sold short.
Short Interest 136.52K Short % of Shares Out 2.23% Short % of Float 7.06% Short Ratio (days to cover) 2.58
Valuation Ratios The PE ratio is -0.01 and the forward
PE ratio is -10.76.
Monopar Therapeutics's PEG ratio is
0.
PE Ratio -0.01 Forward PE -10.76 PS Ratio 0 Forward PS 252.2 PB Ratio 0 P/FCF Ratio -13.02 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Monopar Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.01,
with a Debt / Equity ratio of 0.
Current Ratio 0.01 Quick Ratio 0.01 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.11B Employee Count 14 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 1227.97% in the
last 52 weeks. The beta is 1.06, so Monopar Therapeutics's
price volatility has been higher than the market average.
Beta 1.06 52-Week Price Change 1227.97% 50-Day Moving Average 37.94 200-Day Moving Average 32.84 Relative Strength Index (RSI) 35.88 Average Volume (20 Days) 37,506
Income Statement
Revenue n/a Gross Profit n/a Operating Income -16.16B Net Income -15.59B EBITDA -15.59M EBIT -15.59M Earnings Per Share (EPS) -411.23
Full Income Statement Balance Sheet The company has 45.82M in cash and 0 in
debt, giving a net cash position of 45.82M.
Cash & Cash Equivalents 45.82M Total Debt n/a Net Cash n/a Retained Earnings -75.79B Total Assets 55.09M Working Capital 53.58M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -6.4M
and capital expenditures 0, giving a free cash flow of -6.4M.
Operating Cash Flow -6.4M Capital Expenditures n/a Free Cash Flow -6.4M FCF Per Share -1.69
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields MNPR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for MNPR is $60,
which is 91.4% higher than the current price. The consensus rating is "Buy".
Price Target $60 Price Target Difference 91.4% Analyst Consensus Buy Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 13, 2024. It was a
backward
split with a ratio of 1:5.
Last Split Date Aug 13, 2024 Split Type backward Split Ratio 1:5
Scores Altman Z-Score 82.28 Piotroski F-Score 3
